Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
"Research questions 1. What is the comparative clinical benefit and long-term harm of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 2. What is the optimal dose of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 3. What is the comparative cost-effectiveness of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 4. What is the budget impact for funding treatment with adalimumab, alefacept, efalizumab, etanercept, or infliximab for one year for all Canadian adults with severe plaque psoriasis?" (executive summary)

Project page URL

INAHTA brief and checklist

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal /therapeutic use; Psoriasis /drug therapy

Language Published
English, French

Country of organisation
Canada

Province or state
Ontario

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; Email: publications@cadth.ca

AccessionNumber
32008000100